| NCT ID | NCT07341217 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dr. Chris Gaffney |
| Condition | Colorectal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 86 participants |
| Start Date | 2026-07-07 |
| Primary Completion | 2027-09-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 86 participants in total. It began in 2026-07-07 with a primary completion date of 2027-09-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Colorectal cancer is 37% higher in the North West than the national average and is treated by chemotherapy, including fluorouracil, capecitabine, and oxaliplatin. A side effect of these drugs is loss of memory, forgetfulness, and general brain fog, which can persist for months after the end of treatment. These symptoms are collectively known as 'chemo-brain'. An existing prehabilitation intervention that has been previously developed will be used, which increases fitness and reduces hospital length of stay in colorectal cancer surgery patients, to try to improve the symptoms of chemo-brain in those undergoing chemotherapy and improve quality of life.
Eligibility Criteria
Inclusion Criteria: * Individuals with stage II or III colorectal cancer undergoing chemotherapy with fluorouracil, capecitabine, or oxaliplatin. * Aged 60-85 years old. * Fluent in English * Male and female participants * Not engaged in structured exercise training\* within the six months before providing consent. Exclusion Criteria: * Presence of comorbidities that may significantly alter the metabolic response to exercise (e.g., diabetes mellitus). * Any contraindication to the multivitamin supplementation (Forceval), including known hypercalcaemia, haemochromatosis, peanut or soya allergy, current use of phenytoin or tetracycline antibiotics, and clinically significant impaired renal or hepatic function. * Evidence of pre-existing cognitive impairment, including diagnosis of dementia, other neurodegenerative disorders (e.g., Alzheimer's disease), or clinically indicated mild cognitive impairment. * Diagnosis of atrial fibrillation and haematological malignancy. * Participants without home internet access will be excluded due to the online delivery of the exercise programme. * Diagnosis of profound hearing loss. * Receiving palliative care. * Presence of synchronous cancer. * Structured exercise refers to planned and organised physical activity, such as gym workouts, exercise classes or a team sport, which are designed to improve or maintain physical fitness, often with instruction, rules, and goals.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07341217 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 85 Years, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07341217 currently recruiting?
Yes, NCT07341217 is actively recruiting participants. Contact the research team at c.gaffney@lancaster.ac.uk for enrollment information.
Where is the NCT07341217 trial being conducted?
This trial is being conducted at Blackburn, United Kingdom, Lancaster, United Kingdom, Preston, United Kingdom, Liverpool, United Kingdom.
Who is sponsoring the NCT07341217 clinical trial?
NCT07341217 is sponsored by Dr. Chris Gaffney. The trial plans to enroll 86 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.